Picture [iito] Back into Ad 650x80px
Organisation › Details

Exscientia Ltd. (ex scientia)

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches. Exscientia’s innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development. Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour. Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi, Evotec, Roche and Celgene Exscientia has its headquarters in Oxford, UK with offices in the UK, USA and Japan. *


Period Start 2016-04-26 existent
  Group Exscientia (Group)
  Predecessor University of Dundee
Products Industry drug discovery
  Industry 2 small-molecule cancer drug
Persons Person Hopkins, Andrew (Ex Scientia 201604 CEO)
  Person 2 Taylor, Ben (Exscientia 202011– CFO before Aetion + Tyme Technologies + Goldman Sachs + Barclays)
Region Region Oxford, Oxfordshire
  Country United Kingdom (GB)
  Street 36 St. Giles’
  City OX1 3LD Oxford, Oxfordshire
  Tel +44-1865-818941
    Address record changed: 2021-04-03
Basic data Employees D: 101 to 500 (2021-09-01)
  Currency GBP
  Annual sales 9,672,000 (revenue, consolidated (2020) 2020-12-31)
  Profit -22,283,000 (2020-12-31)
  Cash 62,584,000 (2020-12-31)
    * Document for �About Section�: Exscientia Ltd.. (3/22/19). "Press Release: Exscientia Continues Expansion with Establishment of a Subsidiary in Japan to Target the Pharmaceutical Market Across Asia". Oxford & Osaka.
Record changed: 2021-12-31


Picture [iito] Fighting Customers 650x100px

More documents for Exscientia (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top